StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Viking Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Viking Therapeutics's total assets was $977.17M at Sep 30, 2026. For fiscal 2025 it was $715.73M, down 21.2% from the year before. Over ten years it grew 46.8% a year on average. The highest annual figure on record is $908.32M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$715.73M-21.2%
FY2024Dec 31, 2024$908.32M+146.5%
FY2023Dec 31, 2023$368.49M+118.7%
FY2022Dec 31, 2022$168.53M-20.0%
FY2021Dec 31, 2021$210.66M-17.9%
FY2020Dec 31, 2020$256.50M-9.8%
FY2019Dec 31, 2019$284.26M-6.0%
FY2018Dec 31, 2018$302.31M+1266.6%
FY2017Dec 31, 2017$22.12M+52.2%
FY2016Dec 31, 2016$14.54M-5.9%
FY2015Dec 31, 2015$15.44M+407.3%
FY2014Dec 31, 2014$3.04M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$977.17M+32.2%
Q2 FY2026Jun 30, 2026$521.90M-37.0%
Q1 FY2026Mar 31, 2026$608.24M-29.8%
Q4 FY2025Dec 31, 2025$715.73M-21.2%
Q3 FY2025Sep 30, 2025$739.42M-21.2%
Q2 FY2025Jun 30, 2025$827.85M-12.6%
Q1 FY2025Mar 31, 2025$866.99M-10.4%
Q4 FY2024Dec 31, 2024$908.32M+146.5%
Q3 FY2024Sep 30, 2024$937.89M+145.1%
Q2 FY2024Jun 30, 2024$946.84M+136.3%
Q1 FY2024Mar 31, 2024$967.52M+541.2%
Q4 FY2023Dec 31, 2023$368.49M+118.7%
Q3 FY2023Sep 30, 2023$382.66M+129.6%
Q2 FY2023Jun 30, 2023$400.69M+120.8%
Q1 FY2023Mar 31, 2023$150.90M-22.6%
Q4 FY2022Dec 31, 2022$168.53M-20.0%
Q3 FY2022Sep 30, 2022$166.68M-25.7%
Q2 FY2022Jun 30, 2022$181.51M-23.7%
Q1 FY2022Mar 31, 2022$195.03M-22.0%
Q4 FY2021Dec 31, 2021$210.66M-17.9%
Q3 FY2021Sep 30, 2021$224.47M-14.9%
Q2 FY2021Jun 30, 2021$237.85M-12.3%
Q1 FY2021Mar 31, 2021$250.14M-9.7%
Q4 FY2020Dec 31, 2020$256.50M-9.8%
Q3 FY2020Sep 30, 2020$263.62M-9.1%
Q2 FY2020Jun 30, 2020$271.20M-7.9%
Q1 FY2020Mar 31, 2020$277.10M-7.7%
Q4 FY2019Dec 31, 2019$284.26M-6.0%
Q3 FY2019Sep 30, 2019$290.12M-5.4%
Q2 FY2019Jun 30, 2019$294.49M+103.8%
Q1 FY2019Mar 31, 2019$300.08M+280.0%
Q4 FY2018Dec 31, 2018$302.31M+1266.6%
Q3 FY2018Sep 30, 2018$306.80M+2491.3%
Q2 FY2018Jun 30, 2018$144.47M+908.8%
Q1 FY2018Mar 31, 2018$78.97M+421.2%
Q4 FY2017Dec 31, 2017$22.12M+52.2%
Q3 FY2017Sep 30, 2017$11.84M–
Q2 FY2017Jun 30, 2017$14.32M–
Q1 FY2017Mar 31, 2017$15.15M–
Q4 FY2016Dec 31, 2016$14.54M–

More Viking Therapeutics figures

See a number that looks wrong?